 subcutaneous recombinant human erythropoietin corrects anemia progressive renal failure PURPOSE purpose study data use weekly subcutaneous recombinant human erythropoietin rHuEPO predialysis peritoneal dialysis patients anemia PATIENTS METHODS anemic patients progressive renal failure predialysis home peritoneal dialysis subcutaneous rHuEPO therapy weekly dose Patients observations reason Hematocrit endogenous creatinine clearance new treatment anemia oral iron Iron-deficiency anemia improbable normal red blood cell mean corpuscular volume iron parameters RESULTS hematocrit percentage points weeks patients weekly doses hematocrit patients weeks mean effective dose U/kg patients weekly doses hematocrit mean effective dose U/kg CONCLUSION subcutaneous rHuEPO weekly anemia predialysis peritoneal dialysis patients Weekly dosing convenient patients costly Medicare providers